Hematopoietic stem cell transplantation from a relative HLA-mismatched donor is one option for patients who do not have an immediately available HLA-identical donor and who cannot wait for an appropriate match to be found. 1 However, in such patients graft rejection is one of several significant problems. 1 The immunologic mechanism of graft rejection is thought to be a complex process involving host-derived donor-specific T cells, natural killer cells, 2, 3 and antibody-producing cells. 4 Evidence has been accumulating that the presence of donor-reactive HLA antibodies plays an important role in solid organ graft rejection. 5 Therefore, HLA antibodies need to be removed in order to avoid graft rejection in patients who present with a positive crossmatch for anti-donor lymphocytotoxic antibody. However, routine procedures for carrying out this have not been established. 6 A 34-year-old woman was referred to our hospital in September 2004 for allogeneic hematopoietic transplantation. She had developed acute myeloid leukemia in June 2004 that was refractory to induction therapy with cytarabine and anthracycline. She had no available HLAidentical family donors, and it was determined that, due to disease progression, there was not enough time to await a match from the Japan marrow donor program. There was also no cord blood containing X2.0 Â 10 7 /kg of nucleated cells available in the Japan Cord Blood Bank Network. She had a healthy, partially HLA-mismatched brother, with two-locus mismatches in the host-versus-graft direction and one-locus mismatch in the graft-versus-host direction (Table 1) . Peripheral blood stem cell transplantation (PBSCT) from the brother was planned immediately. However, the patient was found to have HLA antibodies against HLA-A2, which is one of the donor-specific antigens in the host-versus-graft reaction. Her serum showed a positive crossmatch with the lymphocytes obtained from her brother.
Written informed consents were obtained from both patient and donor. It was decided to treat the patient with rituximab and an infusion of donor platelets before transplantation to reduce the amount of circulating HLA antibodies. We processed 40 units of the donor's platelets (day À2) to absorb HLA antibodies before transplantation. 6 After 4-weekly administrations of 600 mg rituximab on days À51, À44, À37 and À30, the patient received a mega-dose (1.06 Â 10 7 cells/kg) of peripheral blood stem cells (PBSCs). The PBSCT was conducted on November 26, 2004, following chemotherapy for cytoreduction. The conditioning regimen consisted of 120 mg/kg of cyclophosphamide and 12 Gy of total body irradiation. Tacrolimus 0.03 mg/kg by continuous infusion and short-term methotrexate were used for graft-versus-host disease prophylaxis. Antidonor lymphocytotoxic antibodies were assayed by lymphocytotoxicity test (LCT) and in an anti-human immunoglobulin lymphocytotoxicity test (AHG-LCT) with donor T and B cells.
The patient's clinical course is shown in Figure 1 . The antibody titer decreased rapidly after the donor platelet transfusion and PBSCT. Finally, on day 6, antibodies were not detectable (Figure 1) . On day 14, neutrophil engraftment of 4500/ml was documented. Chimerism analysis of the peripheral blood by sex chromosomes revealed 98.4% to be of the donor type. The platelet count did not increase after the donor platelet transfusion, and on day 14 platelet engraftment of 50 Â 10 3 /ml had not been reached. This report of successful engraftment in a recipient with a positive crossmatch for antidonor lymphocytotoxic antibody highlights what can be done in such cases. To avoid graft rejection, we gave a donor platelet transfusion, a mega-dose infusion of PBSCs, and administered rituximab prior to transplantation.
Rituximab has recently been reported to be useful in reducing HLA antibodies in patients awaiting renal transplantation. 7 Infusions of rituximab rapidly eliminate CD19 þ and 20 þ cells. Rituximab remains in the serum for 
